hydroxamic acid/neoplasms

Linkul este salvat în clipboard

Alegeți tipul de sortare

Pagină 1 din 37 rezultate

Vorinostat (SAHA) in Uterine Sarcoma

Numai utilizatorii înregistrați pot traduce articole

This is an open-label, single arm, proof of concept-study of the HDAC-inhibitor vorinostat in patients with refractory uterine sarcoma that have been pre-tested for an high expression of HDAC. Patients will receive Vorinostat, 400 mg (4 capsules á 100mg of Zolinza) orally once daily for the first 14

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Numai utilizatorii înregistrați pot traduce articole

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of lymphoproliferative disorder arising from mature T-cells of post-thymic origin. PTCL represent a relatively uncommon group of hematologic malignancies within non-Hodgkin lymphomas (NHL), accounting for about 10% of NHL cases. The

Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy

Numai utilizatorii înregistrați pot traduce articole

Epilepsy surgery is now an accepted and effective management for individuals with drug resistant focal onset epilepsy in carefully selected candidates. This aside, only two RCTs have been performed in adults in temporal lobe epilepsy [1,2], and none in children . Malformations of cortical

Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer

Numai utilizatorii înregistrați pot traduce articole

- A cohort of three patients will be treated at each dose level for one cycle (28 days per cycle). - Treatment will be continued if no DLTs are recorded, and three patients will be treated at the next higher dose level. - If a patient of the cohort develops a DLT, however, another cohort of three

Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer

Numai utilizatorii înregistrați pot traduce articole

PRIMARY OBJECTIVES: I. To evaluate the ability of histone deacetylase (HDAC) inhibition using suberoylanilide hydroxamic acid (SAHA) (vorinostat) to induce expression of the estrogen receptor (ER) and progesterone receptor (PR) genes in solid human triple negative invasive breast

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Numai utilizatorii înregistrați pot traduce articole

In the United States, the incidence of acute myeloid leukemia (AML) is approximately 3.5 cases per 100,000 persons per year. Approximately 13,000 people were diagnosed with AML in 2009 and 9,000 died of the disease, making AML the 6th leading cause of cancer death. Over the past three decades, AML

Vorinostat in Children

Numai utilizatorii înregistrați pot traduce articole

Relapsed or progressive solid tumors and leukemias have a very poor prognosis in children despite intense multimodal treatment protocols involving polychemotherapy, surgery, and radiation. Therefore, innovative treatment strategies targeting specific molecular mechanisms are urgently required. A

Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

Numai utilizatorii înregistrați pot traduce articole

PRIMARY OBJECTIVES: I. To evaluate the efficacy by means of response rate (based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) of vorinostat in the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC). SECONDARY OBJECTIVES: I.

LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors

Numai utilizatorii înregistrați pot traduce articole

The combination of Carboplatin (C) and Paclitaxel (PTX) is considered standard treatment in patients with epithelial ovarian cancer and endometrial cancer, in USA and in those in whom anthracyclines are not recommended. In cervical cancer, where very often the renal function is impaired, C

Development and Exploration of the Feasibility of Using Locally Synthesized Small Molecule Inhibitors to Treat Human Acute Leukemia Cells

Numai utilizatorii înregistrați pot traduce articole

A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

Numai utilizatorii înregistrați pot traduce articole

Key eligibility criteria include: - Newly diagnosed invasive breast cancer awaiting surgery or neoadjuvant (preoperative) treatment - No use of hormone contraceptives or replacement therapy within 30 days prior to the diagnostic breast cancer biopsy (unless willing to have an additional biopsy prior

A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

Numai utilizatorii înregistrați pot traduce articole

Background: - New options for the treatment of patients with advanced thymoma and thymic carcinoma are needed. - Belinostat, N-hydroxy-3-(phenylsulphamoylphenyl) acrylamide, is a hydroxamic acid deacetylase inhibitor that is able to inhibit both histone deacetylase inhibitors (HDAC) Class I and II

Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)

Numai utilizatorii înregistrați pot traduce articole

Phase I design - Three patients will be treated per cohort for one cycle (28 days per cycle). - If no DLTs are recorded, treatment will continue and three patients will be treated in the subsequent cohort. - However, if a patient develops a DLT, another three patients will be treated in this cohort

Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

Numai utilizatorii înregistrați pot traduce articole

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVES: Primary - To determine the efficacy of vorinostat (suberoylanilide hydroxamic acid, SAHA), when administered orally, in a pulsed fashion, once-a-day for 3 consecutive days every week, in inducing a 4% absolute increase or a 100% increase in fetal hemoglobin percent levels (HbF%) in

Anterior
1
2
3
Următor →

Alăturați-vă paginii
noastre de facebook

Herbal & Natural Medicine

Cea mai completă bază de date cu plante medicinale susținută de știință

Funcționează în 55 de limbi
Cure pe bază de plante susținute de știință
Recunoașterea ierburilor după imagine
Harta GPS interactivă - etichetați ierburile în locație (în curând)
Citiți publicațiile științifice legate de căutarea dvs.
Căutați plante medicinale după efectele lor
Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele

Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate